Imre Corp. on Wednesday said it has received Food and DrugAdministration approval to begin clinical trials of its Prosorbacolumn for treatment of patients with rheumatoid arthritis.
The Seattle company (NASDAQ:IMRE), whose products are usedto treat a patient's blood outside the body, said it also plansthis year to conduct trials of its technology in patients withlupus, multiple sclerosis and myasthenia gravis, and withkidney transplants and in certain tumors.
The stock closed at $3.88, picking up $1.19.
(c) 1997 American Health Consultants. All rights reserved.